Tata India Pharma Fund Review: Performance & Strategy
By Business Desk
Explore the Tata India Pharma and Healthcare Fund performance, AUM, top holdings, and strategy based on 2026 data. Ideal for long-term investors.
The Tata India Pharma and Healthcare Fund Direct Growth plan has established a strong medium-to-long-term track record by outperforming its benchmark over 3-year and 5-year periods. Managed by Rajat Srivastava, this sector-focused equity fund navigates high-risk terrain through deliberate sector-specific concentration.
Key Numbers and Fund Metrics
- AUM stands at ₹1,565 Cr as of September 17, 2026.
- NAV is recorded at ₹39.1925 on the same date.
- Demonstrated outperformance spans benchmark comparisons over 3-year and 5-year periods.
- Recent 1-year returns remain modest alongside sector-driven market swings.
Portfolio diversification within the healthcare sector remains a core pillar of the fund strategy. Top holdings consist of Sun Pharmaceutical Industries, Healthcare Global Enterprises, and Divi Laboratories.
Investment Horizon and Strategic Outlook
- Suitability targets investors with a long-term horizon.
- Participants must tolerate short-term volatility and inherent sector swings.
- Short-term gain seekers are less aligned with this thematic exposure.
Consistent performance over extended durations positions the fund as a viable thematic option despite high-risk ratings and modest short-term returns. Investors evaluating this vehicle must weigh sector concentration against proven medium-to-long-term resilience.